.jpg?format=webp&quality=80&width=3840)
Here the study investigates utilization patterns of genetic testing among a contemporary cohort of men with advanced prostate cancer at our institution. A total of 320 men (52.5%) had local/regional disease, and 290 (47.5%) had metastatic disease, 53 (18.3%) of whom had castrate-resistant prostate cancer. Here the study reports that utilization of genetic testing is associated with metastatic disease and inversely associated with age. Overall, utilization rates of genetic testing remain low in all patient groups, including in the metastatic castrate-resistant setting, where genetic testing can identify patients with homologous recombination repair deficiency who may benefit from targeted therapeutics such as PARP inhibitors. Genetic testing in men with aggressive prostate cancer is critical, and barriers to routine testing implementation require further study to develop strategies to improve utilization rates.
Like
Save
Share